• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German–Austrian open-label post-marketing surveillance prospective study
Abstract: The current practice in Germany and Austria, and the safety and efficacy of botulinum toxin type A (BoNT-A; Dysport) in the treatment of patients with post-stroke arm spasticity (with no fixed upper-limb contractures), were assessed in this observational prospective non-interventional study. One treatment cycle was documented with assessments at baseline, approximately week 4 (optional), and approximately week 12. Pattern of spasticity, treatment goal, safety and efficacy were recorded. Overall response and goal achievement was rated on a 4-point scale (‘no goal achievement’, ‘goal achievement’, ‘good g...
Source: Journal of the Neurological Sciences - December 23, 2013 Category: Neurology Authors: Wolfgang H. Jost, Harald Hefter, Andrea Reissig, Katja Kollewe, Joerg Wissel Tags: Original Articles Source Type: research

BOTOX(R) (Botulinum Toxin Type A) Receives a Positive Opinion in Fourteen European Countries for the Treatment of Focal Spasticity of the Ankle in Adult Post Stroke Patients
This Positive Opinion Paves the Way for a Second Indication for BOTOX® in Adult Spasticity Associated with Stroke MARLOW, England, May 1, 2014 -- (Healthcare Sales & Marketing Network) --Today, Allergan Inc. announced that BOTOX® has received a... Biopharmaceuticals, RegulatoryAllergan, BOTOX, Adult Spasticity, limb spasticity, stroke
Source: HSMN NewsFeed - May 1, 2014 Category: Pharmaceuticals Source Type: news

Balancing Burdens and Benefits: Ethical Issues of Off-Label Prescription Pharmaceutical Use
I remember when Botox (Allergen, Irvine, CA) was becoming all the rage in rehabilitation in the mid 1990s. As I recall, the only U.S. Food and Drug Administration (FDA) approved uses at the time were for spasmodic torticollis and blepharospasm. In a short period of time, however, Botox was the new treatment du jour for adults and children alike with spasticity from CP, traumatic brain injury (TBI), and stroke. I also remember feeling a bit queasy about it. Perhaps having recently completed a fellowship in clinical medical ethics colored my view. Images of thousands of people with limb deficiencies, the tragic consequence ...
Source: PM and R - October 1, 2013 Category: Rehabilitation Authors: Ford Vox, Alexander M. Capron, Marilyn F. Kraus, G. Caleb Alexander, Kristi L. Kirschner Tags: Ethical Legal Source Type: research